The director of Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Nicole Williams Sold 974 Shares

Share with your friends










Submit

The director of Intercept Pharmaceuticals  Nicole Williams Sold 974 Shares-Transactions

Nicole Williams Insider Sell Transaction

Based on an average market stock price per share of $278.5, Nicole Williams, the Intercept Pharmaceuticals Inc (NASDAQ:ICPT) ‘s director made a sale of 974 shares of Intercept Pharmaceuticals Inc worth exactly $271,259 U.S Dollars. He also unloaded 973 shares worth approximately $297,115 USD in the last 30 days. This stocks unloading decreased his ownership of Intercept Pharmaceuticals Inc to 0.00% market capitalization or 962 shares.

Intercept Pharmaceuticals Inc Stock Rating, Sentiment and Fundamentals

And also, stats provided by sixteen stock analysts who research Intercept Pharmaceuticals Inc states that the price to earnings ratio will be 0.00 if the earnings for each share is $-8.42. The percentage earnings for each share growth rate YOY is forecasted to be 18.01% or less.

Rating & Sentiment
PsychSignal Social:BUY
Analysts Rating:BUY
Hedge Funds Sentiment:BUY
Stock Fundamentals
Earnings + FCF Trend:BUY
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:UP
MT Trend:UP
LT Trend:UP
OctaFinance Rating*:NEUTRAL

* Read How Our Stock Ratings System Works

Within the last 200 days Intercept Pharmaceuticals Inc’s share price has surged 18.07% and today is in weak uptrend. Because of our proprietary equities momentum model as displayed on the chart below is favourable, we can’t rate the stock SELL as Nicole did with his investment.

Price Chart of Intercept Pharmaceuticals NASDAQ:ICPT Stock

The director of Intercept Pharmaceuticals  Nicole Williams Sold 974 Shares-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

As famous stock speculators such as Felix Zulauf claim, you make the highest risk-adjusted returns through a mix of technical and fundamental analysis. But with Intercept Pharmaceuticals Inc’s stock, it doesn’t look the analysis agree.

Hedge Funds Ownership

As of Q4 2014, 165 hedge funds hold Intercept Pharmaceuticals Inc. In the last quarter, the company had 66.15% institutional ownership. That is a high interest. Its up 23.41% from previous quarter. These stock owners increased the total shares they own by 3.00 million to 15.80 million this quarter. A total of 38 funds opened new positions in Intercept Pharmaceuticals Inc and 75 increased their holdings. There were 50 funds that closed their positions and 38 that reduced them.

HEDGE-FUNDS-LIST-DATABASE-FREE Detwiler Fenton Investment Management Llc had the greatest investment with ownership of 1,492 shares as of Q4 2014 for 0.26% of the fund’s portfolio. Rothschild Investment Corp Il is another bullish player having 2,192 shares of the company or 0.04% of their stocks portfolio. The stock is also 0.03% of the fund’s AUM. The California-based fund Dafna Capital Management Llc have 2.70% of their stock portfolio invested in the stock for 21,900 shares. Moreover, The United Kingdom-based fund Cheyne Capital Management (Uk) Llp disclosed it had purchased a stake worth 1.59% of the fund’s stock portfolio in the company. Samuel Isaly’s Orbimed Advisors Llc was also a notable supporter of the company’s stock, owning 1.49 million shares. Intercept Pharmaceuticals Inc is 2.21% of the fund’s stock portfolio.

Intercept Pharmaceuticals NASDAQ:ICPT Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company�s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA selectively binds to and induces activity in the farnesoid X receptor, or FXR, which has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. It is conducting a Phase III clinical trial of OCA in PBC. Its other products are INT-767 and INT-777.

Today its market worth is: $6.35 billion and it has 21.99 million shares outstanding. The firm has 136 employees. Today the company has 65.10% shareholders and the institutional ownership stands at 65.10%. Intercept Pharmaceuticals Inc was filled in Delaware on 2002-09-04. The stock closed at $280.45001 yesterday and it had average 2 days volume of 107328 shares. It is down from the 30 days average shares volume of 179126. Intercept Pharmaceuticals Inc has a 250 days low of $128.50 and a one year high of $349.05. The current price is above the 200 days simple moving average. Intercept Pharmaceuticals Inc last issued its quarterly earnings information on 03/02/2015. The company reported -1.63 EPS for the quarter, missing the consensus estimate of -1.53 by 0.10. The company had a revenue of 445,000 for 12/31/2014 and 445,000 for 9/30/2014. Therefore, the revenue was down.

Nicole Williams is also Chief Financial Officer of App Pharmaceuticals, Inc., director of Progenics Pharmaceuticals Inc, Orchid Cellmark Inc.

* The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on November 21 – 2014.

* All shares underlying this option have vested.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.